EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers

Sergei Noskov, Olesya Parulya, Lyudmila Lutskova, Anna Arefeva, Ekaterina Protsenko, Veniamin Banko, Kseniia Radaeva, Iuliia Matvienko, Maria Gefen, Polina Karnakova, Alina Knyazeva, Timofey Komarov und 2 weitere

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1463 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Sergei Noskov und 13 weiteren Autor:innen. Beteiligte Einrichtung: City Hospital No. 3, Yaroslavl, Russia. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Cross-Over Studies, Benzimidazoles, Drugs, Generic. Die Arbeit nennt 12 Literaturangaben. Gefördert von: GEROPHARM, Russia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This was an open‐label, randomized, single‐dose, 2‐period, crossover clinical trial with an adaptive design to evaluate the bioequivalence and comparative pharmacokinetics of generic glecaprevir/pibrentasvir versus the brand name product in healthy White male and female volunteers under fed conditions. Safety profiles were also assessed. A total of 56 healthy adult volunteers were enrolled and randomly assigned in a 1:1 ratio to receive a single dose of either the generic or reference formulation. After a 7‐day washout period, subjects received the alternate product. Blood samples were collected at pre‐specified time points up to 48 hours post‐dosing. Plasma concentrations of glecaprevir and pibrentasvir were determined using a validated high‐performance liquid chromatography‐tandem mass spectrometry method. The geometric mean ratios of the test to the reference formulation for maximum plasma concentration (C max ) and area under the concentration‐time curve from drug administration to the last measurable concentration (AUC 0‐t ) fell within the predefined bioequivalence range of 80%‐125%. Both formulations demonstrated comparable pharmacokinetic profiles for glecaprevir and pibrentasvir, and can be considered bioequivalent. No adverse events were reported, and both formulations were well tolerated by all participants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Therapeutic EquivalencyCross-Over StudiesBenzimidazolesDrugs, GenericSulfonamidesPyrrolidinesQuinoxalinesArea Under CurveHealthy VolunteersHumansMaleFemaleAdultYoung AdultMiddle AgedDrug CombinationsTandem Mass SpectrometryAntiviral Agents

Stichwörter der Autor:innen

bioequivalencedirect‐acting antiviral agentsgenericglecaprevirhealthy subjectshepatitis Cpharmacokineticspibrentasvirsafety

Substanzen

BenzimidazolesDrugs, GenericSulfonamidesPyrrolidinesQuinoxalinesDrug Combinationsglecaprevir and pibrentasvirAntiviral Agentspibrentasvir

Autor:innen und Institutionen

  • City Hospital No. 3, Yaroslavl, Russia.
  • R&D Center, GEROPHARM, Saint-Petersburg, Russia.
  • LLC "Center for Pharmaceutical Analytics", Moscow, Russia.

Förderung

  • GEROPHARM, Russia

Zitieren

APA

Noskov, S., Parulya, O., Lutskova, L., Arefeva, A., Protsenko, E., Banko, V., Radaeva, K., Matvienko, I., Gefen, M., Karnakova, P., Knyazeva, A., Komarov, T., Archakova, O., & Shohin, I. (2024). Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1463

Vancouver

Noskov S, Parulya O, Lutskova L, Arefeva A, Protsenko E, Banko V, et al. Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1463

BibTeX
@article{Noskov2024,
  author = {Noskov, Sergei and Parulya, Olesya and Lutskova, Lyudmila and Arefeva, Anna and Protsenko, Ekaterina and Banko, Veniamin and Radaeva, Kseniia and Matvienko, Iuliia and Gefen, Maria and Karnakova, Polina and Knyazeva, Alina and Komarov, Timofey and Archakova, Olga and Shohin, Igor},
  title = {Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1463}
}
Kostenlos starten →